NLS Pharma, a Swiss-based biotech group focussing on treatments for attention deficit hyperactivity disorder and other neurological disorders, has completed a Series B founding round. The company has as well completed a Phase 2 study of its lead compound.
NLS Pharma (NLS) is a Swiss-based biotech group founded in 2015 focusing on compounds to treat ADHD, sleep disorders and cognitive impairment. NLS welcomes a group of new investors and advisors who participated in the series B funding:
- Thomas Ebeling, CEO & President, ProSiebenSat.1 Media SE and a 20-year biopharmaceutical industry veteran whose extensive worldwide leadership positions include serving as CEO of the global Pharmaceutical business at Novartis.
- Professor Claus Christiansen, MD, co-founder and Chairman of the Nordic Bioscience Group, as well as a distinguished scientist, successful entrepreneur, and founder of the Center for Clinical and Basic Research (CCBR).
- Hervé Girsault, formerly Global Head of Mergers & Acquisitions, Business Development and Strategy at Novartis Consumer Health, among other global leadership positions at the company.
"NLS pairs an increasingly rare new investment opportunity in a potentially large market with an investigational compound that has already completed Phase 2,” said Thomas Ebeling. “The ADHD patient population is vast, underserved and there is a need to reduce systemic reliance on traditional stimulants with alternative treatments that may enable long-term administration. I am impressed by the speed with which NLS Pharma has advanced NLS-1 to date, and look forward to contributing to its potential continued success.”
“These are exciting times at NLS Pharma and we are grateful for this demonstration of confidence from such a dynamic and experienced group of new investors who will enrich the expertise and resources required to execute our aggressive strategy,” said Alex Zwyer, CEO at NLS Pharma Group. “The clinical progress to date of NLS-1 is one source of great optimism, and the outlook for our ADHD franchise as a whole is further brightened by new patents and our broader pipeline.”
In addition to the investment, the company has recently announced the following major milestones:
- Completion of the Phase 2 study NLS-1001, a double-blind Placebo-Controlled Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of NLS-1 (mazindol) in Adults with DSM-5 ADHD. NLS-1 is a potential alternative to stimulants for the treatment of ADHD. Phase 2 results will be available in the coming weeks.
- NLS recently secured four new patents within its ADHD franchise for the U.S., Europe and Japan.
(Press Release)
Please login or sign up to comment.
Commenting guidelines